Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Dacomitinib for EGFR positive lung cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 05.06.17
Views: 1637
Rating:

Dr Tony Mok, The Chinese University of Hong Kong, Shatin, China

Dr Mok presents results at an ASCO 2017 press briefing session from the ARCHER 1050 trial, a phase III trial of dacomitinib, a second-generation EGFR inhibitor, compared to gefitinib.

He describes the increased efficacy of dacomitinib, boosting median PFS to 14.7 months compared to 9.2 months with gefitinib, but also that this stronger activity comes at the cost of more severe GI toxicities, requiring does modification.

 

Related videos

follow us

WIN 2019


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation